Paricalcitol and cardiorenal outcome: From the IMPACT study to clinical practice

Antonio Bellasi, Andrea Galassi, Paolo Salvi, Mario Cozzolino

Research output: Contribution to journalArticlepeer-review


Chronic kidney disease mineral bone disorders (CKD-MBD) encompass laboratory, vascular and bone abnormalities that might portend a poor prognosis in CKD. In spite of a great effort in elucidating the CKD-MBD natural history and pathogenesis, the underlying mechanisms are still largely unknown. However, a deficit in vitamin D is commonly reported as one of the first steps in CKD-MBD, and numerous epidemiological studies have associated serum vitamin D levels with different markers of cardiovascular disease and the risk of death in different populations. We herein summarize current evidence that links vitamin D deficiency to an adverse outcome and the results of the most recent clinical trials that have investigated the impact of paricalcitol supplementation on hard outcome in CKD patients.

Original languageEnglish
Pages (from-to)12-16
Number of pages5
JournalBlood Purification
Issue number1
Publication statusPublished - Jun 2013


  • Cardiovascular risk factors
  • Chronic kidney disease mineral bone disorder
  • Surrogate outcome
  • Survival
  • Vitamin D

ASJC Scopus subject areas

  • Nephrology
  • Hematology


Dive into the research topics of 'Paricalcitol and cardiorenal outcome: From the IMPACT study to clinical practice'. Together they form a unique fingerprint.

Cite this